Switzerland's top-funded tech companies in H1 2026

Swiss tech firms raised over €1.1 billion in the first half of 2026, with a majority of the capital flowing into just ten companies. Series A funding proved particularly attractive, with several large transactions driving significant investment. Seed and pre-seed activity remained diversified across numerous smaller rounds. Later-stage funding, especially Series C and E, also played a substantial role.

Semiconductors garnered the most attention, with €281 million in funding, followed by energy (€223 million) and healthtech (€220 million). Cleantech and fintech also saw notable investment, while software and other tech sectors experienced a higher number of smaller transactions. Overall, the Swiss funding landscape featured a diverse mix of early-stage activity and a concentrated few large rounds in capital-intensive industries like semiconductors, energy, and healthtech.

Here are the top ten companies that raised the most in H1 2026: Kandou AI secured $225 million to expand its AI connectivity chip production, engage with hyperscale and AI infrastructure clients, and develop next-generation chips and IP. Terralayr received €192 million to grow its grid-scale battery storage portfolio in Germany and extend its LAYR energy flexibility platform.

CeQur raised $100 million in Series E funding to broaden its commercial presence, enhance sales operations, and further develop its CeQur Simplicity insulin-delivery patch. SWISSto12 obtained €73 million in ESA-backed support for the development and industrialisation of its HummingSat satellite systems and phased-array antenna technologies.

BLP Digital attracted $50 million from Goldman Sachs Alternatives to bolster its AI-powered automation platform for core business processes. Polares Medical secured $50 million in Series C funding to advance its MRace Posterior Leaflet Replacement system and clinical trials across the US, Europe, and Australia. PAVE Space raised $40 million in seed funding to advance its orbital transportation infrastructure, including the LYOBA heavy-lift kickstage and IBEX high-mobility platform.

NUCLIDIUM, a clinical-stage biotech company, received €28.6 million to develop copper-based radiopharmaceuticals for cancer diagnosis and treatment.